SIRIO Pharma has reported record revenues in the APAC region, with the construction set to begin on a major new manufacturing facility in Thailand in Q4 2025.
Growth has been driven by rising demand across Southeast Asia, with key markets including Singapore, Australia and emerging hubs in Thailand and Indonesia.
This expansion reflects a strategic commitment to localise offerings in line with evolving consumer preferences.
As an innovation-led CDMO, Sirio has worked closely with its partners to anticipate trends and accelerate novel product development, helping brand’s to be first to market with best-in-class nutraceuticals.
In the past 12 months, Sirio has seen rising demand for fish oil supplements, multivitamins and high-dosage sports nutrition gummies in Australia, and collagen-based beauty supplements, biotin and sour-flavoured sports nutrition gummies in Singapore.
The company now expects new high-growth markets in Thailand, Indonesia and India – typically follower markets – to emerge in the next few years and will start construction on a large local manufacturing facility in Thailand in Q4 2025 to meet demand.
Sirio’s growth in Southeast Asia is being driven by fast-evolving consumer trends across key markets.
In Australia, rising demand for muscle gain and recovery products is transforming the sports nutrition landscape.
Consumers are opting for convenient, high-efficacy formats as alternatives to traditional powders.
To meet this demand, the company has introduced high-dosage performance gummies featuring protein, creatine, and BCAAs, offering functional benefits without the need for pills or mixing.
In Thailand, the popularity of active lifestyles is driving uptake of microeffervescent vitamins and sports gummies.
Indonesia, meanwhile, is experiencing a surge in interest for halal-certified supplements, alongside growing demand for Zone IVB-stable formulations that can streamline regulatory approvals.
India, in contrast, has seen rapidly improving popularity for vegetarian softgels and beauty supplements — particularly those featuring collagen and biotin — which highlights a broader shift toward clean-label, plant-based preferences.
“These shifts across Southeast Asia are accelerating demand for innovative formats,” said Alex Du, General Manager, Asia Pacific BU at Sirio Pharma.
“We’re focused on helping our partners bring differentiated products to market quickly. Our innovation-led model enables them to lead in emerging categories — often securing first-mover advantage."
"Together with our partners, we’re growing rapidly across these high-potential nutraceutical markets”
Women’s health is also a key growth engine across the region. Sirio has developed next-generation formulations featuring collagen, biotin, iron, and bioavailable peptides to support holistic well-being.
Technologies such as its collagen-based gummy – developed without traditional gelling agents – allow for cleaner labels and higher active loads, giving brands a clear edge in competitive markets.
With its expanded regional footprint – including a new Singapore office and upcoming manufacturing facility in Thailand – Sirio is well positioned to scale quickly in response to local demand.